Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Cardiol ; 205: 249-258, 2023 10 15.
Artigo em Inglês | MEDLINE | ID: mdl-37619491

RESUMO

There are limited and conflicting data on the initial management of intermediate-risk (or submassive) pulmonary embolism (PE). This study sought to compare the outcomes of catheter-directed thrombolysis (CDT) in combination with systemic anticoagulation (SA) to SA alone. A systematic search was conducted in MEDLINE, EMBASE, PubMed, and the Cochrane databases from inception to March 1, 2023 for studies comparing the outcomes of CDT + SA versus SA alone in intermediate-risk PE. The outcomes were in-hospital, 30-day, 90-day, and 1-year mortality; bleeding; blood transfusion; right ventricular recovery; and length of stay. Random-effects models was used to calculate the pooled incidence and risk ratios (RRs) with 95% confidence intervals (CIs). A total of 15 (2 randomized and 13 observational) studies with 10,549 (2,310 CDT + SA and 8,239 SA alone) patients were included. Compared with SA, CDT + SA was associated with significantly lower in-hospital mortality (RR 0.41, 95% CI 0.30 to 0.56, p <0.001), 30-day mortality (RR 0.34, 95% CI 0.18 to 0.67, p = 0.002), 90-day mortality (RR 0.34, 95% CI 0.17 to 0.67, p = 0.002), and 1-year mortality (RR 0.58, 95% CI 0.34 to 0.97, p = 0.04). There were no significant differences between the 2 cohorts in the rates of major bleeding (RR 1.39, 95% CI 0.72 to 2.68, p = 0.56), minor bleeding (RR 1.83, 95% CI 0.97 to 3.46, p = 0.06), and blood transfusion (RR 0.34, 95% CI 0.10 to 1.15, p = 0.08). In conclusion, CDT + SA is associated with significantly lower short-term and long-term all-cause mortality, without any differences in major/minor bleeding, in patients with intermediate-risk PE.


Assuntos
Catéteres , Embolia Pulmonar , Humanos , Bases de Dados Factuais , Embolia Pulmonar/tratamento farmacológico , Anticoagulantes/uso terapêutico , Terapia Trombolítica , Ensaios Clínicos Controlados Aleatórios como Assunto
2.
Methodist Debakey Cardiovasc J ; 19(4): 100-103, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37547896

RESUMO

Marantic endocarditis is a rare condition associated with autoimmune disease, malignancy, and hypercoagulable states. It is characterized by sterile friable vegetations composed of fibrin and platelets that confer a high risk of systemic embolism. Here we showcase imaging that led to the diagnosis of an interesting case of marantic endocarditis secondary to metastatic malignancy.


Assuntos
Adenocarcinoma de Pulmão , Endocardite não Infecciosa , Endocardite , Neoplasias Pulmonares , Humanos , Adenocarcinoma de Pulmão/complicações , Endocardite/diagnóstico , Endocardite/diagnóstico por imagem , Endocardite não Infecciosa/etiologia , Endocardite não Infecciosa/complicações , Neoplasias Pulmonares/complicações , Neoplasias Pulmonares/diagnóstico por imagem
3.
Front Immunol ; 14: 1148209, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37266425

RESUMO

Inflammation contributes to many chronic conditions. It is often associated with circulating pro-inflammatory cytokines and immune cells. GLP-1 levels correlate with disease severity. They are often elevated and can serve as markers of inflammation. Previous studies have shown that oxytocin, hCG, ghrelin, alpha-MSH and ACTH have receptor-mediated anti-inflammatory properties that can rescue cells from damage and death. These peptides have been studied well in the past century. In contrast, GLP-1 and its anti-inflammatory properties have been recognized only recently. GLP-1 has been proven to be a useful adjuvant therapy in type-2 diabetes mellitus, metabolic syndrome, and hyperglycemia. It also lowers HbA1C and protects cells of the cardiovascular and nervous systems by reducing inflammation and apoptosis. In this review we have explored the link between GLP-1, inflammation, and sepsis.


Assuntos
Diabetes Mellitus Tipo 2 , Peptídeo 1 Semelhante ao Glucagon , Humanos , Peptídeo 1 Semelhante ao Glucagon/uso terapêutico , Peptídeo 1 Semelhante ao Glucagon/metabolismo , Diabetes Mellitus Tipo 2/tratamento farmacológico , Peptídeos/uso terapêutico , Inflamação/tratamento farmacológico , Anti-Inflamatórios/farmacologia , Anti-Inflamatórios/uso terapêutico
4.
Front Immunol ; 13: 864007, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35572539

RESUMO

Sepsis is a potentially life-threatening systemic inflammatory syndrome characterized by dysregulated host immunological responses to infection. Uncontrolled immune cell activation and exponential elevation in circulating cytokines can lead to sepsis, septic shock, multiple organ dysfunction syndrome, and death. Sepsis is associated with high re-hospitalization and recovery may be incomplete, with long term sequelae including post-sepsis syndrome. Consequently, sepsis continues to be a leading cause of morbidity and mortality across the world. In our recent review of human chorionic gonadotropin (hCG), we noted that its major properties including promotion of fertility, parturition, and lactation were described over a century ago. By contrast, the anti-inflammatory properties of this hormone have been recognized only more recently. Vasopressin, a hormone best known for its anti-diuretic effect, also has anti-inflammatory actions. Surprisingly, vasopressin's close cousin, oxytocin, has broader and more potent anti-inflammatory effects than vasopressin and a larger number of pre-clinical studies supporting its potential role in limiting sepsis-associated organ damage. This review explores possible links between oxytocin and related octapeptide hormones and sepsis-related modulation of pro-inflammatory and anti-inflammatory activities.


Assuntos
Hormônios Peptídicos , Sepse , Anti-Inflamatórios/uso terapêutico , Feminino , Humanos , Ocitocina/uso terapêutico , Sepse/complicações , Sepse/tratamento farmacológico , Vasopressinas
5.
Front Immunol ; 12: 714177, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34589085

RESUMO

Sepsis continues to be a major cause of morbidity, mortality, and post-recovery disability in patients with a wide range of non-infectious and infectious inflammatory disorders, including COVID-19. The clinical onset of sepsis is often marked by the explosive release into the extracellular fluids of a multiplicity of host-derived cytokines and other pro-inflammatory hormone-like messengers from endogenous sources ("cytokine storm"). In patients with sepsis, therapies to counter the pro-inflammatory torrent, even when administered early, typically fall short. The major focus of our proposed essay is to promote pre-clinical studies with hCG (human chorionic gonadotropin) as a potential anti-inflammatory therapy for sepsis.


Assuntos
Anti-Inflamatórios/uso terapêutico , Gonadotropina Coriônica/uso terapêutico , Peptídeos/uso terapêutico , Sepse/tratamento farmacológico , Animais , Anti-Inflamatórios/química , Anti-Inflamatórios/metabolismo , Bactérias/metabolismo , Gonadotropina Coriônica/química , Gonadotropina Coriônica/metabolismo , Síndrome da Liberação de Citocina/tratamento farmacológico , Glicoproteínas/química , Glicoproteínas/metabolismo , Humanos , Inflamação , Peptídeos/química , Peptídeos/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...